

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT

- (1) PROPOSED CHANGE OF NON-EXECUTIVE DIRECTORS, THE CHAIRMAN AND THE AUTHORIZED REPRESENTATIVE;
- (2) CHANGE IN COMPOSITION OF BOARD COMMITTEES; AND
- (3) CLOSURE OF THE REGISTER OF MEMBERS

(1) PROPOSED CHANGE OF NON-EXECUTIVE DIRECTORS, THE CHAIRMAN AND THE AUTHORIZED REPRESENTATIVE

Resignation of Non-executive Directors, the Chairman and the Authorized Representative

The board (the “**Board**”) of directors (the “**Directors**”) of Sinopharm Group Co. Ltd. (the “**Company**”) hereby announces that on 28 November 2025, due to the work arrangement, Mr. Zhao Bingxiang (“**Mr. Zhao**”) tendered his resignation to the Board as a non-executive Director, the chairman (the “**Chairman**”) of the Board, the chairman of the nomination committee of the Board (the “**Nomination Committee**”), the chairman of the strategy and investment committee of the Board (the “**Strategy and Investment Committee**”), a member of the legal and compliance and environmental, social and governance committee of the Board (the “**Legal and Compliance and Environmental, Social and Governance Committee**”) and the authorized representative (the “**Authorized Representative**”) of the Company (pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

Exchange of Hong Kong Limited (the “**Listing Rules**”), and Ms. Feng Rongli (“**Ms. Feng**”) tendered her resignation to the Board as a non-executive Director, a member of the remuneration committee of the Board and a member of the Nomination Committee. Each of the above resignations shall take effect from the appointment of their respective replacement at the general meeting of the Company.

Both of Mr. Zhao and Ms. Feng confirmed that they have no disagreement with the Board and there is no other matter relating to their resignations that needs to be brought to the attention of the shareholders (the “**Shareholders**”) and creditors of the Company.

During the term of office, Mr. Zhao diligently and faithfully performed his duties. The Board would like to take this opportunity to express its sincere gratitude to his contribution in several aspects such as the sustainable and stable development of the Company, effectively responding to challenges and preventing risk, as well as improving the efficiency of corporate governance of listed company.

During the term of office, Ms. Feng diligently and faithfully performed her duties. The Board would like to take this opportunity to express its sincere gratitude to her contribution to ensure the Company's promotion of organizational reform and stable development.

Proposed Appointments of Non-executive Directors

On the same day, the Board resolved to propose to appoint Mr. Jin Bin (“**Mr. Jin**”) and Ms. Li Ying (“**Ms. Li**”) as non-executive Directors (the “**Proposed Appointment of Directors**”).

The above Proposed Appointments of Directors were proposed by the Nomination Committee according to the nomination procedures for Directors of the Company and based on the needs of the Company and have been submitted to the Board for review after considering the Director candidate's relevant qualification by the Nomination Committee, and will then be submitted by the Board to the general meeting for final approval.

In accordance with the articles of association of the Company (the “**Articles of Association**”), the above Proposed Appointments of Directors are subject to the approval by the Shareholders at the general meeting of the Company.

Upon the approval of the above Proposed Appointments of Directors by the Shareholders, the Company will enter into service contracts with them, respectively, and their terms of office as Directors shall commence from the date of their appointments by the general meeting and end on the expiration of the term of the current session of the Board. Pursuant to the Articles of Association, they will be subject to

retirement by rotation and re-election upon the expiry of their terms of office. Their remuneration will be determined by the Board according to the authorization granted at the general meeting of the Company and in accordance with the Company's remuneration standard regarding Directors implemented from time to time. According to the Company's current remuneration standard, non-executive Directors will not receive any remuneration from the Company.

Biographies of Mr. Jin and Ms. Li

Mr. Jin Bin, aged 52, obtained a master's degree in business administration from Beijing Jiaotong University. Mr. Jin joined China National Medicines Corporation Ltd. (國藥集團藥業股份有限公司) in 2005, and served as the business supervisor of the office of China National Medicines Corporation Ltd.. Mr. Jin joined China National Pharmaceutical Group Co., Ltd. (中國醫藥集團有限公司) ("CNPGC") in 2008, and successively holding positions including the deputy director of the administrative department, the deputy director of the office and the director of the office. Mr. Jin has served as the deputy general manager of CNPGC since November 2022 and has served as the general legal counsel and the chief compliance officer of CNPGC since April 2025.

Ms. Li Ying, aged 52, obtained a master's degree in agricultural economics and management from the School of Economics and Management of Northeast Agricultural University in 2000. Ms. Li possesses extensive experience in equity investment within the pharmaceutical industry, she has served as the director of the Beijing Bureau of China Banking and Insurance Regulatory Commission, the deputy general manager of the equity business department of China Huarong Financial Asset Management Co., Ltd., and a member of the party committee and deputy general manager of Huarong Ruitong Equity Investment Management Co., Ltd.. Ms. Li is currently the deputy general manager of the first asset management department of China CITIC Financial Asset Management Co., Ltd.

Save as disclosed above, as at the date of this announcement, Mr. Jin and Ms. Li did not have any relationship with any Director, senior management or substantial or controlling Shareholder of the Company, or have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, Mr. Jin and Ms. Li did not hold any other positions in the Company or any of its subsidiaries, or any directorship in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matter that needs to be brought to the attention of the Shareholders or any matter in relation to the Proposed Appointments of Directors that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.

Election of the Chairman and Authorized Representative

The Board hereby announces that on 28 November 2025, the Board resolved to elect Mr. Jin as the Chairman and the Authorized Representative. The positions of Mr. Jin as the Chairman and the Authorized Representative shall take effect upon the approval of his appointment as a non-executive Director by Shareholders at the general meeting of the Company.

(2) CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board further announces that on 28 November 2025, the Board resolved to elect Mr. Jin as the chairman of the Nomination Committee, the chairman of the Strategy and Investment Committee and a member of the Legal and Compliance and Environmental, Social and Governance Committee. The positions of Mr. Jin as the chairman of the Nomination Committee, the chairman of the Strategy and Investment Committee and a member of the Legal and Compliance and Environmental, Social and Governance Committee shall take effect upon the approval of his appointment as a non-executive Director by Shareholders at the general meeting of the Company.

(3) CLOSURE OF THE REGISTER OF MEMBERS

The Company proposed to convene and hold an extraordinary general meeting on Friday, 19 December 2025 to seek the approval of the Shareholders with respect to the Proposed Appointments of Directors. Pursuant to the articles of association of the Company, for the purpose of holding the extraordinary general meeting, the register of members of the Company (the “**Register**”) will be closed from Tuesday, 16 December 2025 to Friday, 19 December 2025 (both days inclusive), during which no transfer of shares of the Company will be registered. In order to be qualified to attend and vote at the extraordinary general meeting, for holders of H shares of the Company, all transfer documents accompanied by the relevant share certificates must be lodged with the H share registrar of the Company, Computershare Hong Kong Investor Services Limited (address: Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong) as soon as practicable, and in any event no later than 4:30 p.m. on Monday, 15 December 2025.

Shareholders whose names appear on the Register on Tuesday, 16 December 2025 are entitled to attend and vote at the extraordinary general meeting.

A circular containing, among other things, details of the Proposed Appointments of Directors will be despatched to the Shareholders in due course according to the manner in which the Shareholders of the Company have elected to receive corporate communications.

By order of the Board
Sinopharm Group Co. Ltd.
Zhao Bingxiang
Chairman

Shanghai, the PRC
28 November 2025

As at the date of this announcement, the executive Director is Mr. Lian Wanyong; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.